Blinatumomab for Leukemia, Lymphocytic, Acute, L1
This study is evaluating whether a combination of immunotherapy drugs may help treat certain types of leukemia.
See full descriptionAbout the trial for Leukemia, Lymphocytic, Acute, L1
Treatment Groups
This trial involves 2 different treatments. Blinatumomab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex of any age. You must have received newly diagnosed for Leukemia, Lymphocytic, Acute, L1 or one of the other 7 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Blinatumomab will improve 2 primary outcomes, 7 secondary outcomes, and 6 other outcomes in patients with Leukemia, Lymphocytic, Acute, L1. Measurement will happen over the course of From the first day of treatment on the study until death or last known follow up, assessed up to 2 years.
Patient Q & A Section
Has blinatumomab proven to be more effective than a placebo?
Blinatumomab demonstrated both superiority and equivalence relative to the placebo arm. Given the small sample size, it is of course unclear if statistically significant differences exist.
What are the common side effects of blinatumomab?
As blinatumomab is highly effective in patients with refractory lymphoma it is essential to minimize its side effects. The most serious side effects reported in the post-marketing studies were infusion reactions, gastrointestinal disorders, infections and peripheral neuropathy.
What are the signs of leukemia, lymphocytic, acute, l1?
Symptoms vary depending on the type of leukemia a person has. Symptoms such as blood problems, fever, feeling tired and unexplained weight loss may be signs of leukemia. Certain symptoms can be linked to some subtypes of leukemia that are harder to treat. A bone marrow examination is usually necessary to diagnose leukemia. In leukemia, leukemia cells tend to spread and go to different places in the body (for example, bone marrow). A bone marrow examination can help doctors to look at how well the marrow is working. Some of the first symptoms of leukemia are fatigue, shortness of breath or chest pain.
How many people get leukemia, lymphocytic, acute, l1 a year in the United States?
The American Cancer Society estimates there will be 6,640 new diagnoses of acute lymphocytic leukemia, 4930 new diagnoses of acute myelogenous leukemia, 7,060 new diagnoses of acute lymphocytic leukemia, and 3,620 new diagnoses of acute myelogenous leukemia in 2020. The American Cancer Society estimates there will be 2,520 new diagnoses of chronic lymphocytic leukemia, 1,180 new diagnoses of chronic myelogenous leukemia, 2,230 new diagnoses of chronic myelogenous leukemia, and 530 new diagnoses of chronic lymphocytic leukemia in 2020.
What is leukemia, lymphocytic, acute, l1?
Leukemia/lymphocytic, acute and [acute lymphoblastic leukemia](https://www.withpower.com/clinical-trials/acute-lymphoblastic-leukemia)s are the leukemias associated with primary immunodeficiency disease or chronic infections. They are usually associated with a predisposition to the disease or infection. Chronic myeloid leukemia is another example of primary immunodeficiency disease and is not associated with infectious agents.
What are common treatments for leukemia, lymphocytic, acute, l1?
The typical or 'classical' ALL treatments include: (1) prednisone, (2) vincristine, (3) chlorambucil, (4) doxorubicin, (5) amorphous aluminum phosphate, (6) cyclophosphamide, (7) methotrexate, (8) mercaptopurine, (9) intrathecal methotrexate, (10) lomustine, (11) mercaptopurine, (12) hydroquinone, and (13) melengestrol.
What causes leukemia, lymphocytic, acute, l1?
Leukemia is not a single disease; its cause is complex, but it is believed to be a combination of several factors, including exposure to certain environmental hazards, genetic predisposition, and certain illnesses resulting in immune deficiency. Lymphocytic, acute, and chronic leukemias are commonly understood as separate diseases. The lymphocytic acute disease usually presents with fever, fatigue, and anemia. The exact cause may be an infection by one of the four herpes viruses; it frequently appears in people with some other viral infections. The exact cause of the chronic lymphocytic disease is not well understood. Acute lymphocytic leukemia is not a single disease, but rather a group of disorders which may be caused by the same genes.
Can leukemia, lymphocytic, acute, l1 be cured?
We have found no support for a cure for lymphatic leukemias. Even though a cure for the lymphatic leukemias has not been found in the literature with either a chemical or irradiatonal cure, a cure for lymphatic leukemias remains a possibility because most of them are curable and some show improvement in response to treatment.
Is blinatumomab typically used in combination with any other treatments?
In the retrospective analysis of the present study, blinatumomab was used as monotherapy or in combination with other treatments in more than 20% of patients.
Who should consider clinical trials for leukemia, lymphocytic, acute, l1?
There is no clear-cut evidence to conclude whether patients with lymphocytic leukemia should be included in clinical trials for aggressive therapy or those with low grade chronic lymphocytic leukemias are appropriate candidates for standard therapies. Inappropriate trials of aggressive therapies are less likely for patients with high grade chronic lymphocytic leukemias.
Does blinatumomab improve quality of life for those with leukemia, lymphocytic, acute, l1?
BL inhibits leukemia-related symptoms for CLL patients better than a standard of care. Patients treated with BL had significantly fewer symptoms than patients who received standard of care, especially in regards to fatigue and nausea.
How quickly does leukemia, lymphocytic, acute, l1 spread?
In two of 10 patients, lymphocytic, acute, l1 was localized to the kidneys. This suggests that lymphocytic, acute, l1 may have more extensive metastatic dissemination compared with other subtypes. The short survival times and small number of patients in this study should be taken into account when designing treatment trials.